https://www.selleckchem.com/products/gsk8612.html
Critical to this will be the development of new diagnostic tests that are better than currently available LTBI tests at predicting who is at risk of progression to active TB disease. The diagnostic product development portfolio for LTBI appears to have reached the end of the road. Every attempt to make optimal use of currently available IGRAs using WHO LTBI guidelines for LTBI testing and treatment must be made to achieve WHO End TB strategy targets. Mutations in X-linked gene methyl-CpG-binding protein 2 (MECP2), a key transcriptional
Like
Comment
Share
